- Home
- GLTO vs ONFO Comparison
GLTO vs ONFO Comparison
Compare GLTO & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ONFO
- Stock Information
- Founded
- GLTO 2011
- ONFO 2018
- Country
- GLTO Denmark
- ONFO United States
- Employees
- GLTO N/A
- ONFO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- GLTO Health Care
- ONFO Technology
- Exchange
- GLTO Nasdaq
- ONFO Nasdaq
- Market Cap
- GLTO 6.5M
- ONFO 6.7M
- IPO Year
- GLTO 2020
- ONFO 2022
- Fundamental
- Price
- GLTO $4.51
- ONFO $1.31
- Analyst Decision
- GLTO Buy
- ONFO
- Analyst Count
- GLTO 1
- ONFO 0
- Target Price
- GLTO $10.00
- ONFO N/A
- AVG Volume (30 Days)
- GLTO 14.7K
- ONFO 18.5K
- Earning Date
- GLTO 03-07-2025
- ONFO 11-15-2024
- Dividend Yield
- GLTO N/A
- ONFO N/A
- EPS Growth
- GLTO N/A
- ONFO N/A
- EPS
- GLTO N/A
- ONFO N/A
- Revenue
- GLTO N/A
- ONFO $6,590,171.00
- Revenue This Year
- GLTO N/A
- ONFO $133.59
- Revenue Next Year
- GLTO N/A
- ONFO N/A
- P/E Ratio
- GLTO N/A
- ONFO N/A
- Revenue Growth
- GLTO N/A
- ONFO 29.25
- 52 Week Low
- GLTO $4.24
- ONFO $0.39
- 52 Week High
- GLTO $23.50
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- GLTO 39.75
- ONFO 48.15
- Support Level
- GLTO $4.39
- ONFO $1.35
- Resistance Level
- GLTO $4.84
- ONFO $1.48
- Average True Range (ATR)
- GLTO 0.31
- ONFO 0.11
- MACD
- GLTO 0.00
- ONFO 0.01
- Stochastic Oscillator
- GLTO 26.73
- ONFO 28.95
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.